|Bid||20.18 x 1100|
|Ask||36.10 x 1300|
|Day's Range||20.21 - 22.27|
|52 Week Range||10.56 - 45.82|
|Beta (5Y Monthly)||1.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.00|
HAYWARD, Calif., September 02, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the upcoming virtual H.C. Wainwright Global Investment Conference.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
HAYWARD, Calif., August 19, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Mitchell E. Levinson to the newly created role of Chief Strategy Officer, effective immediately, in addition to the continuation of his role as a member of the Pulse Biosciences Board of Directors.